IL183944A0 - Combination therapy comprising telmisartan and hydrochlorothiazide - Google Patents

Combination therapy comprising telmisartan and hydrochlorothiazide

Info

Publication number
IL183944A0
IL183944A0 IL183944A IL18394407A IL183944A0 IL 183944 A0 IL183944 A0 IL 183944A0 IL 183944 A IL183944 A IL 183944A IL 18394407 A IL18394407 A IL 18394407A IL 183944 A0 IL183944 A0 IL 183944A0
Authority
IL
Israel
Prior art keywords
telmisartan
hydrochlorothiazide
combination therapy
therapy
combination
Prior art date
Application number
IL183944A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL183944(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL183944A0 publication Critical patent/IL183944A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
IL183944A 2004-12-17 2007-06-14 Combination therapy comprising telmisartan and hydrochlorothiazide IL183944A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
IL183944A0 true IL183944A0 (en) 2007-10-31

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183944A IL183944A0 (en) 2004-12-17 2007-06-14 Combination therapy comprising telmisartan and hydrochlorothiazide

Country Status (15)

Country Link
EP (1) EP1827424A1 (zh)
JP (1) JP2008524136A (zh)
KR (1) KR20070097511A (zh)
CN (1) CN101080225A (zh)
AR (1) AR052052A1 (zh)
AU (1) AU2005315855A1 (zh)
BR (1) BRPI0519656A2 (zh)
CA (1) CA2589493A1 (zh)
EA (1) EA200701159A1 (zh)
IL (1) IL183944A0 (zh)
NO (1) NO20072325L (zh)
PE (1) PE20060768A1 (zh)
TW (1) TW200637546A (zh)
UY (1) UY29274A1 (zh)
WO (1) WO2006063737A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
SI2180882T1 (sl) * 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Trdni matriksni farmacevtski pripravek
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20110008428A1 (en) 2008-03-19 2011-01-13 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
CN102164918B (zh) * 2008-07-31 2014-05-07 武田药品工业株式会社 固体药物组合物
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
ES2847904T3 (es) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
EP1854454B1 (en) * 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan

Also Published As

Publication number Publication date
PE20060768A1 (es) 2006-09-29
TW200637546A (en) 2006-11-01
AU2005315855A1 (en) 2006-06-22
WO2006063737A1 (en) 2006-06-22
NO20072325L (no) 2007-07-06
KR20070097511A (ko) 2007-10-04
CN101080225A (zh) 2007-11-28
BRPI0519656A2 (pt) 2009-03-03
JP2008524136A (ja) 2008-07-10
EP1827424A1 (en) 2007-09-05
UY29274A1 (es) 2006-07-31
AR052052A1 (es) 2007-02-28
EA200701159A1 (ru) 2007-12-28
CA2589493A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
IL183944A0 (en) Combination therapy comprising telmisartan and hydrochlorothiazide
IL190055A0 (en) Quinolines and their therapeutic use
GB0625659D0 (en) Therapeutic compounds and their use
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
EP1874800A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
EP1781685A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS
EP1838288A4 (en) THERAPEUTIC MATERIALS AND METHODS
AP2007004024A0 (en) Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles
IL185575A0 (en) Benzoxazocines and their therapeutic use
EP1778228A4 (en) THERAPEUTIC CONNECTION AND TREATMENTS
ZA200802683B (en) Quinolines and their therapeutic use
GB0614538D0 (en) Therapeutic Compounds And Their Use
EP2234667A4 (en) DETERMINATION AND METHODS OF ADMINISTERING A TREATMENT
GB0427723D0 (en) Compounds and their use
GB0405405D0 (en) Assays and medical treatments
GB0421767D0 (en) Compounds and their medical uses
GB0421766D0 (en) Compounds and their medical uses
GB0512551D0 (en) Methods and therapeutic treatments
GB0506127D0 (en) Chloride and its therapeutic use
EP1759703A4 (en) IMMUNOSTIMULATING AGENT AND INTERF ROGEN
GB0625633D0 (en) Therapeutic compounds and their use
GB0506129D0 (en) Iodide and its therapeutic use
GB0416876D0 (en) Compound and use in treatment
GB0421917D0 (en) Cancer diagnosis and therapy